This is the authors' abstract. We don't add key points for this paper.
Introduction Precancerous lesions of gastric cancer (PLGC) represent a critical stage for intervention using traditional Chinese medicine (TCM) to prevent the development of gastric cancer (GC). As a widely used Chinese patent medicine for treating chronic gastritis in clinical practice, the molecular mechanisms of Moluodan Concentrated Pill (MLD) in PLGC remain unclear. Methods The chemical constituents of MLD were characterized using ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS), and the potential targets of its 18 herbal components were identified using the TCMSP and HERB databases. PLGC-related targets were retrieved from the DisGeNET and GeneCards databases, and the overlapping targets were identified by taking the intersection and subjected to functional enrichment analysis. A pharmacological network linking active components to shared targets was constructed, along with a protein-protein interaction (PPI) network, both visualized using Cytoscape 3.7.2. The top five hub genes identified from the PPI network, along with their corresponding active components were selected for molecular docking. Subsequently, a PLGC rat model was established using a four-factor modeling approach and treated with MLD. The findings from network pharmacology were validated through Western blotting, ELISA, HE staining, AB-PAS staining, HID-AB staining, and immunofluorescence assays. Results A total of 65 major compounds in MLD were identified. Network analysis indicated that MLD might exert its anti-PLGC effects by regulating key targets such as PI3K, AKT1, STAT3, EGFR, and SRC, thereby modulating the PI3K/AKT and EGFR signaling pathways. Moreover, its active components exhibited strong binding affinity for EGFR pathway proteins. Animal experiments demonstrated that MLD significantly alleviated pathological damage in gastric tissue, restored the ultrastructure of gastric mucosa, reduced the levels of PGC and TNF-α in peripheral blood, and downregulated the expression of PCNA, β-catenin, and EGFR in gastric mucosa. Collectively, MLD inhibited the progression of PLGC to GC by regulating the EGFR signaling axis. Conclusions MLD may exert significant therapeutic effects in PLGC by synergistically regulating multiple components and targets to modulate key signaling pathways such as PI3K/AKT and EGFR, and by inhibiting inflammation and abnormal proliferation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: